Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

Cancers

Eva Rettinger¹  Nawid Albinger¹  Tobias Bexte¹  Philipp Wendel¹  Evelyn Ullrich¹  Leander Künnemeyer¹  Lisa Marie Reindl¹  Andreas Mackensen²  Vinzenz Särchen³  Tobias Bopp⁴ 

[1] Children’s Hospital, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Goethe-University Frankfurt, 60590 Frankfurt am Main, Germany;Department of Medicine 5, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany;Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, 60528 Frankfurt am Main, Germany;Institute for Immunology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;

关键词: NK cell;    T cell;    CIK cell;    NK-92;    cell therapy;    immune therapy;   

DOI  :  10.3390/cancers13061481

来源: DOAJ

【 摘 要 】

The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible “off-the-shelf” therapeutic concept. Recent approaches have successfully enhanced the specificity and cytotoxicity of T, NK, CIK or NK-92 cells towards tumor-specific or associated target antigens generated by genetic engineering of the immune cells, e.g., to express a chimeric antigen receptor (CAR). Here, we will look into the history and recent developments of T and NK cell-based immunotherapy.

【 授权许可】

Unknown